Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066716 · ClinicalTrials.gov registry record · Phase 2
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00066716 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 39 participants.
The verdict
NCT00066716, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. Celecoxib may also stop the growth of tumor cells by stopping blood flow to the tumor and/or may block the enzymes necessary for their growth. Combining celecoxib with paclitaxel and carboplatin before surgery may shrink the tumor so that it can be removed during surgery. Giving celecoxib alone after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well giving celecoxib together with paclitaxel and carboplatin works in treating patients who are undergoing surgery for esophageal cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- PROCEDURE conventional surgery
- PROCEDURE adjuvant therapy
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066716
The ClinicalTrials.gov registry entry for NCT00066716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00066716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066716 about?
NCT00066716 is a clinical study titled "Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus". RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. Celecoxib may also stop t...
What is the current status of trial NCT00066716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2003-06.
What interventions are being tested in trial NCT00066716?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), conventional surgery (PROCEDURE), adjuvant therapy (PROCEDURE), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00066716?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.